Transforming growth factor-β1 small interfering RNA regulates platelet-derived growth factor and phosphorylated extracellular regulated protein kinase in rats with hepatic fibrosis: an experimental study
10.3760/cma.j.issn.1007-3418.2017.09.010
- VernacularTitle: 转化生长因子β1 siRNA调控肝纤维化大鼠血小板衍生生长因子及磷酸化细胞外调节蛋白激酶的研究
- Author:
Xiaofang ZHOU
1
;
Yujie JIANG
1
;
Yan ZHANG
1
;
Hang SUN
2
;
Qi LIU
2
;
Xiaofeng SHI
1
Author Information
1. Department of Infectious Diseases, the Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China
2. Key Laboratory of Molecular Biology for Infectious Diseases, Ministry of Education and Department of Infectious Diseases, Chongqing Medical University, Chongqing 400016, China
- Publication Type:Journal Article
- Keywords:
Hepatic cirrhosis;
Transforming growth factor-beta 1;
Platelet-derived growth factor;
Extracellular regulated protein kinase
- From:
Chinese Journal of Hepatology
2017;25(9):701-705
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the impact of transforming growth factor-β1 (TGF-β1) silencing by small interfering RNA (siRNA) on the expression of platelet-derived growth factor-β (PDGF-BB) and its receptor (PDGF-βR) in rats with hepatic fibrosis.
Methods:A total of 40 male Sprague-Dawley rats were randomly divided into normal control group, model group, TGF-β1 siRNA treatment group, and negative control group. All rats except those in the normal control group were given subcutaneous injection of 40% carbon tetrachloride to establish a rat model of hepatic fibrosis. The rats in the negative control group and the TGF-β1 siRNA treatment group were given tail vein injection of negative control plasmid or TGF-β1 siRNA plasmid twice a week at a dose of 0.25 mg/kg, and those in the normal control group and the model group were given the injection of sterile isotonic saline twice a week. The rats were sacrificed after 12 weeks and liver tissue samples were collected. Real-time PCR, immunohistochemistry, and Western blot were used to measure the expression of PDGF-BB, PDGF-βR, and phosphorylated extracellular signal-regulated kinase 1/2 (p-ERK1/2) in liver tissue. A one-way analysis of variance, the q test, and the Kruskal-Wallis test were used for statistical analysis based on data type.
Results:Compared with the model group and the negative control group, the TGF-β1 siRNA treatment group had significantly inhibited mRNA and protein expression of PDGF-BB and PDGF-βR (F = 24.785 and 22.92, P < 0.01), as well as significantly inhibited expression of p-ERK1/2 (P < 0.05).
Conclusion:Targeted TGF-β1 siRNA can effectively downregulate the expression of PDGF-BB, PDGF-βR, and p-ERK1/2 in liver tissue and thus help to improve hepatic fibrosis.
